Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Design of Novel Target-Oriented Chemotherapeutic Anti-cancer Agents with ADME Pharmacokinetics"
A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Pharmacology and Drug Metabolism".
Deadline for manuscript submissions: 31 July 2023 | Viewed by 2165
Special Issue Editors
Interests: biochemistry; molecular; anti-cancer; natural products
Interests: medicinal chemistry; organic chemistry; computational chemistry; drug design; drug repurposing
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Cancer, as uncontrolled cell proliferation, is the second-leading cause of death worldwide. The present chemotherapy protocols have significant limitations in selectivity and target efficacy. Hence, anti-cancer activity still presents a promising area of research for finding effective and selective anti-cancer agents, so designing novel chemotherapeutics with target-oriented pathways will be of added value. In the context of updated and continuous drug discovery, the term "computer-aided drug design" (CADD) refers to a wide variety of theoretical and computational methodologies that have been employed in predicting the three-dimensional molecular structures of receptors, enzymes, and nucleic acids as molecular models of drug–receptor complexes for designing novel inhibitors with altered recognition and receptor-affinity properties. CADD helps in finding rationalized synthetic compounds or semisynthetic natural compounds against apoptosis, angiogenesis, and metastasis downstream signaling pathway. Additionally, rationalized design helps in studying drug metabolism, drug–target interactions, and ADME pharmacokinetics.
Therefore, this Special Issue deals with designing novel chemotherapeutic agents (synthetic- or natural-based compounds) against both cellular and molecular pathways as selective anti-cancer agents.
Dr. Mohamed S. Nafie
Dr. Ahmed A. Al-karmalawy
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- natural-based compounds
- target-oriented mechanisms
- novel synthetic compounds